Butterfly Network Inks $252M-Funded Merge Labs for Ultrasound BCI Push — Butterfly Network, Inc.

Event summary

Butterfly Network (NYSE: BFLY) partners with Merge Labs for ultrasound-based brain-computer interfaces (BCI) via multi-year licensing deal.
Merge Labs, backed by $252M in seed funding, gains exclusive access to Butterfly’s Poseidon Family of Ultrasound-on-Chip™ technology.
Deal includes upfront payments, milestone-based royalties, and hardware purchase commitments for Butterfly.
Butterfly to host inaugural BCI Innovation Summit on September 2, 2026, convening industry leaders.

The big picture

Butterfly Network’s partnership with Merge Labs signals a strategic pivot toward non-medical applications of its Ultrasound-on-Chip technology, aligning with broader industry trends in neural interfaces. The deal underscores the growing convergence of semiconductor innovation and AI-driven healthcare solutions, with Butterfly positioning itself as a key enabler in the rapidly evolving BCI field. The $252M backing of Merge Labs highlights the high-stakes nature of this emerging market.

What we're watching

Technology Integration: How Merge Labs will leverage Butterfly’s Ultrasound-on-Chip technology to accelerate BCI development.
Market Expansion: Whether Butterfly can sustain growth beyond medical imaging into BCI and other non-competitive healthcare markets.
Competitive Dynamics: The pace at which other semiconductor firms may enter the BCI space, challenging Butterfly’s exclusivity.